BENGALURU (Reuters) – Indian pharmaceutical firm Gennova Biopharmaceuticals’ mRNA-based COVID-19 vaccine was found to be safe and effective in an early-stage study, the country’s drug regulator said https://pib.gov.in/PressReleseDetail.aspx?PRID=1748520 on Tuesday.
Health authorities have allowed the company to conduct further studies to test the vaccine’s efficacy.
(Reporting by Shivani Singh in Bengaluru; Editing by Ramakrishnan M.)
